<TABLE>
<CAPTION>
<S> <C>
-----------------------------
OMB APPROVAL
SECURITIES AND EXCHANGE COMMISSION -----------------------------
Washington, D.C. 20549 OMB Number:
Expires:
Estimated average burden
FORM 12b-25 hours per response ..... 2.50
-----------------------------
-----------------------------
NOTIFICATION OF LATE FILING COMMISSION FILE NUMBER
0-12374
(Check One): |X| Form 10-K |_| Form 20-F |_| Form 11-K |_| Form 10-Q |_| Form N-SAR -----------------------------
-----------------------------
CUSIP NUMBER
294592 30 8
For Period Ended: DECEMBER 31, 1997 -----------------------------
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended: ___________________________________________________________________________________________
- ------------------------------------------------------------------------------------------------------------------------------------
Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
- ------------------------------------------------------------------------------------------------------------------------------------
If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:
____________________________________________________________________________________________________________________________________
PART I -- REGISTRANT INFORMATION
____________________________________________________________________________________________________________________________________
Full Name of Registrant
IMMUNE RESPONSE, INC.
____________________________________________________________________________________________________________________________________
Former Name if Applicable
____________________________________________________________________________________________________________________________________
Address of Principal Executive Office (Street and Number)
7315 EAST PEAKVIEW AVENUE
ENGLEWOOD, COLORADO 80111
____________________________________________________________________________________________________________________________________
City, State and Zip Code
PART II -- RULE 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check appropriate box.)
| (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable
| effort or expense;
|
|X| | (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR,
| or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the
| subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth
| calendar day following the prescribed due date; and
|
| (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
PART III -- NARRATIVE
State below in reasonable detail why the Form 10-K, 11-K, 20-F 10-Q, N-SAR, or the transition report or portion thereof, could not
be filed within the prescribed time period. (Attach Extra Sheets if Needed.)
IMMUNE RESPONSE, INC., A COLORADO CORPORATION, HEREBY REQUESTS AN EXTENSION UNTIL APRIL 14, 1998 FOR THE FILING OF ITS ANNUAL
REPORT ON FORM 10-KSB FOR THE YEAR ENDED DECEMBER 31, 1997. THIS ADDITIONAL TIME IS NECESSARY IN ORDER FOR THE REGISTRANT AND ITS
AUDITORS TO COMPLETE THE PREPARATION OF THE REQUIRED FINANCIAL STATEMENTS AS WELL AS PARTS ONE THROUGH FOUR OF THE FILING.
SEC 1344 (6/94)
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
PART IV--OTHER INFORMATION
<C> <S>
(1) Name and telephone number of person to contact in regard to this notification
JOSEPH W. HOVORKA 303 796-8139
____________________________________________ _______________________________ _________________________________________________
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of
1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such
shorter period that the registrant was required to file such report(s) been filed? If the answer
is no, identify report(s). |X| Yes |_| No
--------------------------------------------------------------------------------------------------------------------------------
(3) Is it anticipated that any significant change in results of operations from the corresponding period
for the last fiscal year will be reflected by the earnings statements to be included in the subject
report or portion thereof? |_| Yes |X| No
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the
reasons why a reasonable estimate of the results cannot be made.
====================================================================================================================================
IMMUNE RESPONSE, INC.
____________________________________________________
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
MARCH 31, 1998 /S/ JOSEPH W. HOVORKA, PRESIDENT
Date _____________________________________ By_____________________________________________________
INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The
name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf
of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to
sign on behalf of the registrant shall be filed with the form.
- ----------------------------------------------------------- ATTENTION --------------------------------------------------------------
Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).
- ------------------------------------------------------------------------------------------------------------------------------------
GENERAL INSTRUCTIONS
1. This form is required by Rule 12b-25 of the General Rules and Regulations under the Securities Exchange Act of 1934.
2. One signed original and four conformed copies of this form and amendments thereto must be completed and filed with the
Securities and Exchange Commission, Washington, D.C. 20549, in accordance with Rule 0-3 of the General Rules and Regulations
under the Act. The information contained in or filed with the form will be made a matter of public record in the Commission
files.
3. A manually signed copy of the form and amendments thereto shall be filed with each national securities exchange on which any
class of securities of the registrant is registered.
4. Amendments to the notifications must also be filed on form 12b-25 but need not restate information that has been correctly
furnished. The form shall be clearly identified as an amended notification.
5. ELECTRONIC FILERS. This form shall not be used by electronic filers unable to timely file a report solely due to electronic
difficulties. Filers unable to submit a report within the time period prescribed due to difficulties in electronic filing should
comply with either Rule 201 or Rule 202 of Regulation S-T or apply for an adjustment in filing date pursuant to Rule 13(b) of
Regulation S-T.
</TABLE>
(102196DTI)
<PAGE>
DAVIS & CO., CPA'S, P.C.
9137 EAST MINERAL CIRCLE, SUITE 110
ENGLEWOOD, COLORADO 80112-3402
(303) 792-3900, FAX (303) 792-2811
March 31, 1998
Mr. Joseph W. Hovorka, President
Immune Response, Inc.
7315 East Peakview Avenue
Englewood, CO 80111
Dear Mr. Hovorka:
You have furnished to us a copy of your "Notification of Late Filing" on Form
12-b-25, dated March 31, 1998.
We are in agreement with the comments made under Part III of the Form
with respect to the reasons why we are unable to furnish our report on the
financial statements of Immune Response, Inc. on or before the date the Form
10-KSB of Immune Response, Inc., for the year ended December 31, 1997, is
required to be filed.
Sincerely,
DAVIS & CO., CPAs, P.C.
/S/ CAROL A. DAVIS
Carol A. Davis
Certified Public Accountant
CAD/sek